Skip Nav Destination
Issues
1 December 2007
-
Cover Image
Cover Image
CDP791 is a PEGylated di-Fab′ antibody that binds with high affinity to VEGFR2 and blocks VEGF binding. In a Phase I clinical trial of CDP791, several patients developed cutaneous hemangiomata arising 28 to 106 days after the first drug administration and resolving after cessation. The cover shows immunohistochemical analysis of a hemangioma biopsy indicating that VEGFR2 is nonphosphorylated. Additional immunohistochemistry shows the presence of CDP791 and suggests inhibition of VEGFR2 signaling in these lesions. For further details, please see the article by Ton and associates on page 7113 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
Human Cancer Biology
Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?
The German Glioma Network; Michael Weller; Hilmar Berger; Christian Hartmann; Johannes Schramm; Manfred Westphal; Matthias Simon; Roland Goldbrunner; Dietmar Krex; Joachim P. Steinbach; Christoph B. Ostertag; Markus Loeffler; Torsten Pietsch; Andreas von Deimling
Imaging, Diagnosis, Prognosis
Stem Cell Marker Nestin and c-Jun NH2-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme: Possible Prognostic Implications
Annunziato Mangiola; Gina Lama; Cecilia Giannitelli; Pasquale De Bonis; Carmelo Anile; Libero Lauriola; Giuseppe La Torre; Giovanni Sabatino; Giulio Maira; Meena Jhanwar-Uniyal; Gigliola Sica
A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy
Yingye Zheng; Dionyssios Katsaros; Shannon J.C. Shan; Irene Rigault de la Longrais; Mauro Porpiglia; Andreas Scorilas; Nam W. Kim; Robert L. Wolfert; Iris Simon; Lin Li; Ziding Feng; Eleftherios P. Diamandis
Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma
Rainer Riesenberg; Christoph Weiler; Oliver Spring; Martin Eder; Alexander Buchner; Tanja Popp; Mirna Castro; Robert Kammerer; Osamu Takikawa; Rudolf A. Hatz; Christian G. Stief; Alfons Hofstetter; Wolfgang Zimmermann
Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma
Saskia A.G.M. Cillessen; Corine J. Hess; Erik Hooijberg; Kitty C.M. Castricum; Pim Kortman; Fedor Denkers; Wim Vos; Mark A. van de Wiel; Gerrit J. Schuurhuis; Gert J. Ossenkoppele; Chris J.L.M. Meijer; Joost J. Oudejans
NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model
Jean-Simon Diallo; Abdulhadi Aldejmah; Abdelali Filali Mouhim; Benjamin Péant; Mona Alam Fahmy; Ismaël Hervé Koumakpayi; Kanishka Sircar; Louis R. Bégin; Anne-Marie Mes-Masson; Fred Saad
Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials
Claire H. Seedhouse; Martin Grundy; Paul White; Yun Li; Janet Fisher; Darya Yakunina; Anthony V. Moorman; Terence Hoy; Nigel Russell; Alan Burnett; Monica Pallis
High-risk Human Papillomavirus E7 Oncoprotein Detection in Cervical Squamous Cell Carcinoma
Sigrun Ressler; René Scheiden; Kerstin Dreier; Andreas Laich; Elisabeth Müller-Holzner; Haymo Pircher; Dieter Morandell; Ines Stein; Hans-Peter Viertler; Frédéric R. Santer; Andreas Widschwendter; Jos Even; Pidder Jansen-Dürr; Catherine Capesius; Werner Zwerschke
Cancer Therapy: Clinical
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Jeffrey Haessler; John D. Shaughnessy, Jr.; Fenghuang Zhan; John Crowley; Joshua Epstein; Frits van Rhee; Elias Anaissie; Mauricio Pineda-Roman; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; Guido Tricot; Bart Barlogie
BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
Susan Branford; John F. Seymour; Andrew Grigg; Chris Arthur; Zbigniew Rudzki; Kevin Lynch; Timothy Hughes
Glucocorticoids in the Treatment of Children with Acute Lymphoblastic Leukemia and Hodgkin's Disease: A Pilot Study on the Adverse Psychological Reactions and Possible Associations with Neurobiological, Endocrine, and Genetic Markers
Rosemarie Felder-Puig; Christiane Scherzer; Michaela Baumgartner; Magdalena Ortner; Claudia Aschenbrenner; Christian Bieglmayer; Till Voigtländer; E. Renate Panzer-Grümayer; Wim J.E. Tissing; Jan W. Koper; Karl Steinberger; Christian Nasel; Helmut Gadner; Reinhard Topf; Michael Dworzak
Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome
Michael Grövdal; Rasheed Khan; Anni Aggerholm; Petar Antunovic; Jan Astermark; Per Bernell; Lena-Maria Engström; Lars Kjeldsen; Olle Linder; Lars Nilsson; Anna Olsson; Jonas Wallvik; Jon Magnus Tangen; Gunnar Öberg; Sten Eirik Jacobsen; Peter Hokland; Anna Porwit; Eva Hellström-Lindberg
Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2
N.C. Ton; G.J.M. Parker; A. Jackson; S. Mullamitha; G.A. Buonaccorsi; C. Roberts; Y. Watson; K. Davies; S. Cheung; L. Hope; F. Power; J. Lawrance; J. Valle; M. Saunders; R. Felix; J.A. Soranson; L. Rolfe; K. Zinkewich-Peotti; G.C. Jayson
First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer
Arkadiusz Z. Dudek; Carla Yunis; Lester I. Harrison; Sandeep Kumar; Ronald Hawkinson; Sarah Cooley; John P. Vasilakos; Kevin S. Gorski; Jeffrey S. Miller
Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4α, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics
Lai-San Tham; Nicholas H.G. Holford; Sok-Ying Hor; Theresa Tan; Lingzhi Wang; Rui-Chen Lim; How-Sung Lee; Soo-Chin Lee; Boon-Cher Goh
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Monica E. Loghin; Michael D. Prados; Patrick Wen; Larry Junck; Frank Lieberman; Howard Fine; Karen L. Fink; Minesh Metha; John Kuhn; Kathleen Lamborn; Susan M. Chang; Timothy Cloughesy; Lisa M. DeAngelis; Ian H. Robins; Kenneth D. Aldape; W.K. Alfred Yung
Cancer Therapy: Preclinical
Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme
Chunsheng Liu; Jann N. Sarkaria; Cory A. Petell; Georgia Paraskevakou; Paula J. Zollman; Mark Schroeder; Brett Carlson; Paul A. Decker; Wenting Wu; C. David James; Stephen J. Russell; Evanthia Galanis
Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts
William C. Zamboni; Sandra Strychor; Erin Joseph; Dustin R. Walsh; Beth A. Zamboni; Robert A. Parise; Margaret E. Tonda; Ning Y. Yu; Charles Engbers; Julie L. Eiseman
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds